<dfn id='4oiib'><optgroup id='4oiib'></optgroup></dfn><tfoot id='4oiib'><bdo id='4oiib'><div id='4oiib'></div><i id='4oiib'><dt id='4oiib'></dt></i></bdo></tfoot>

          <ul id='4oiib'></ul>

          • Skip to main page content
            Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
            . 2021 Apr 19.
            doi: 10.1038/s41586-021-03530-2. Online ahead of print.

            Adjuvanting a subunit COVID-19 vaccine to induce protective immunity


            Adjuvanting a subunit COVID-19 vaccine to induce protective immunity

            Prabhu S Arunachalam et al. Nature. .


            The development of a portfolio of COVID-19 vaccines to vaccinate the global population remains an urgent public health imperative1. Here we demonstrate the capacity of a subunit vaccine, comprising the SARS-CoV-2 spike receptor binding domain displayed on a protein nanoparticle (RBD-NP), to stimulate robust and durable neutralizing antibody (nAb) responses and protection against SARS-CoV-2 in non-human primates. We evaluated five adjuvants including Essai O/W 1849101, a squalene-in-water emulsion; AS03, an alpha-tocopherol-containing oil-in-water emulsion; AS37, a TLR-7 agonist adsorbed to Alum; CpG1018-Alum, a TLR-9 agonist formulated in Alum; and Alum. RBD-NP immunization with AS03, CpG1018-Alum, AS37 or Alum induced substantial nAb and CD4 T cell responses, and conferred protection against SARS-CoV-2 infection in the pharynges, nares and bronchoalveolar lavage. Live-virus nAb response was maintained up to 180 days post-vaccination with RBD/AS03, and correlated with protection. RBD-NP immunization cross-neutralized the B.1.1.7 variant efficiently but showed a reduced response against the B.1.351 variant. While RBD-NP/AS03 demonstrated a 4.5-fold reduction in neutralization of B.1.351, the RBD-NP/AS37 group showed a 16-fold reduction, suggesting differences in the breadth of the nAb response induced by these adjuvants. Furthermore, RBD-NP/AS03 was as immunogenic as a prefusion stabilized Spike immunogen (Hexapro) adjuvanted with AS03. These data highlight the efficacy of the adjuvanted RBD-NP vaccine in promoting protective immunity against SARS-CoV-2, and have paved the way for the clinical evaluation of this vaccine in Phase I/II clinical trials (NCT04742738 and NCT04750343).

            Similar articles

            Associated data

            LinkOut - more resources